Proteomics says the Chicago launch has fired the starting gun on a broader commercial strategy targeting licensing, distribution and health insurance partnerships across the US.
To support the push, the company plans to present fresh clinical evidence comparing PromarkerD’s performance against standard care, as part of the association’s Late Breaking Abstracts program – an initiative designed to deliver important and timely research developments.
The US rollout comes hot on the heels of PromarkerD’s Australian release three months ago, where the test was sold for the first time in a targeted campaign across Western Australia and the Northern Territory.
Proteomics says the domestic campaign gave it a perfect opportunity to fine-tune the company’s logistics and consumer engagement models in preparation for US expansion.
Backed by rigorous science and a clearly articulated path to market, Proteomics’ PromarkerD appears to be emerging as a flagship diagnostic tool in the fight against diabetic kidney disease.
Should the rollout prove successful, the test could change lives and reshape an entire segment of chronic disease management in the world’s most expensive healthcare system.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
- For more: Elrisala website and for social networking, you can follow us on Facebook
- Source of information and images “brisbanetimes”“
